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Mitochondria are functionally and physically associ-
ated with heterotypic membranes, yet little is known
about how these interactions impact mitochondrial
outer-membrane permeabilization (MOMP) and apo-
ptosis. We observed that dissociation of heterotypic
membranes from mitochondria inhibited BAK/BAX-
dependent cytochrome c (cyto c) release. Biochem-
ical purification of neutral sphingomyelinases that
correlated with MOMP sensitization suggested that
sphingolipid metabolism coordinates BAK/BAX acti-
vation. Using purified lipids and enzymes, sensitivity
to MOMP was achieved by in vitro reconstitution
of the sphingolipid metabolic pathway. Sphingolipid
metabolism inhibitors blocked MOMP from heavy
membrane preparations but failed to influence
MOMP in the presence of sphingolipid-reconstituted,
purified mitochondria. Furthermore, the sphingolipid
products, sphingosine-1-PO4 and hexadecenal, co-
operated specifically with BAK and BAX, respec-
tively. Sphingolipid metabolism was also required
for cellular responses to apoptosis. Our studies sug-
gest thatBAK/BAXactivationandapoptosisarecoor-
dinated throughBH3-onlyproteinsandaspecific lipid
milieu that is maintained by heterotypic membrane-
mitochondrial interactions.INTRODUCTION
Mitochondria are dynamic organelles that interact with each
other and heterotypic intracellular membrane compartments,988 Cell 148, 988–1000, March 2, 2012 ª2012 Elsevier Inc.such as the endoplasmic reticulum (ER) (Csordas et al., 2006;
de Brito and Scorrano, 2008). It is proposed that mitochondria
are structurally and functionally tethered to organelles via pro-
teins that reside in the outer mitochondrial membrane (OMM),
and that these organelle-organelle interactions form unique
biochemical and physical loci that regulate lipid biosynthesis,
lipid transport, and intra-organellar Ca2+ signaling (Hayashi
et al., 2009; Scorrano et al., 2003; Walter and Hajnoczky, 2005).
An area of particular interest is the impact of organelle communi-
cation on apoptosis.
The mitochondrial pathway of apoptosis is dependent upon
the BCL-2 family for the release of proapoptotic factors (e.g.,
cyto c) from the mitochondrial intermembrane space (IMS), via
the process of mitochondrial outer-membrane permeabilization
(MOMP) (Chipuk et al., 2010). The BCL-2 family is divided into
three functional groups based on their composition of up to
four BCL-2 homology domains (BH1-4 domains) (Chipuk et al.,
2010). Anti-apoptotic BCL-2 proteins (e.g., BCL-xL) function to
directly bind and inhibit the proapoptotic BCL-2 proteins. The
proapoptotic members are divided into two classes. The effector
molecules (e.g., BAK, BAX) directly engage MOMP by creating
proteolipid pores responsible for cyto c release (Kuwana et al.,
2002; Lindsten et al., 2000; Wei et al., 2000; Wei et al., 2001).
The BH3-only proteins function in distinct cellular stress path-
ways to either directly activate BAK/BAX-dependent MOMP
(e.g., BID), or by inhibiting the anti-apoptotic repertoire (e.g.,
BAD), which alters sensitivity to the direct activators and effec-
tors (Chipuk et al., 2008; Kuwana et al., 2005; Letai et al., 2002).
Sphingolipid metabolism also regulates apoptosis, but how
sphingolipids mechanistically intersect with BCL-2 family func-
tion remains obscure (Hannun and Obeid, 2008). Apoptotic in-
ducers promote alterations in sphingolipid profiles, in particular
ceramide profiles (Taha et al., 2006b). Exogenous ceramides
applied to cells promotes apoptosis (Obeid et al., 1993); and
genetic or pharmacological inhibition of ceramide production
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Figure 1. Microsomes Restore Mito-
chondrial Sensitivity to Direct Activator
Stimulation
(A) HM and mitochondria were treated with
C8-BID (0.5, 1, and 5 nM).
(B) The HM fraction was isolated, and the mS and
mitochondrial (Mito) fractions were purified. All
three fractions were subjected to western blot. In
parallel, each fraction was incubated with 10 nM
C8-BID for 1 hr at 37C, washed, and subjected to
western blot.
(C) Same as in (A), but treatments included BID
BH3 and BIM BH3 (1, 5, and 20 mM).
(D) HM (50 mg) and mitochondria (50 mg) were
treated as indicated (C8-BID, 1 nM; BID BH3,
5 mM; BCL-xL, 500 nM; mS, 5, 25, and 50 mg).
(E) HM, mitochondrial, and mS fractions were
subjected to western blot.
(F) HM, mitochondrial, and mS fractions were
treated with limited proteolysis, lysed, and sub-
jected to western blot.
(G) Purification scheme to identify SMPD3 and
SMPD4.
See also Figure S1.can result in apoptotic resistance (Alphonse et al., 2004; Liu
et al., 2004; Pchejetski et al., 2005; Rodriguez-Lafrasse et al.,
2002; Taha et al., 2006a)(Dai et al., 2004; Deng et al., 2008;
Mesicek et al., 2010). A challenge remains to determine if sphin-
golipids and the BCL-2 family cooperate to regulate MOMP.
Here we show that mitochondria actively maintain a sphingolipid
milieu that promotes BAK/BAX function and apoptosis.
RESULTS
Microsomes Restore Mitochondrial Sensitivity to Direct
Activator Stimulation
The isolation of heavymembrane (HM) fractions usually results in
mitochondria that are contaminated with ER markers. Using
a refinement of a published protocol (Csordas et al., 2006), weCell 148, 988–10eliminated the majority of ER contami-
nation and were able to obtain a highly
pure mitochondrial population (Figures
S1A-B). This purified fraction was desig-
nated mitochondria, whereas the subse-
quent light membrane, heterotypic frac-
tion was termed microsomes (mS). We
then examined the influence of these
heterotypic species on mitochondrial
sensitivity to recombinant caspase-8
cleaved BID (C8-BID)-induced BAK acti-
vation and cyto c release. BAK is the
effector molecule under investigation in
these experiments because C57Bl/6 liver
HM fractions only contain BAK due to its
integrationwithin theOMM.BAX is acyto-
solic effector protein and does not copur-
ify using standard HM isolation tech-
niques. In Figure 1A, HM fractions weretreated with C8-BID and this resulted in a dose-dependent
release of cyto c as measured by a change in localization from
the pellet (p) to the supernatant (s). In comparison, mitochondria
purified from the HM fraction were treated with the same doses
of C8-BID and demonstrated reduced cyto c release, requiring
10-20 fold higher C8-BID concentrations to achieve minimal
release.
To determine if resistance to C8-BID induced cyto c release
was due to decreased binding of C8-BID to mitochondria, we
incubated the HM and mitochondrial fractions with C8-BID,
washed the fractions, and subjected them to western blot for
associated BID. Both fractions bound equal amounts of the
BID p15 fragment suggesting the decreased sensitivity of mito-
chondria was independent of BID association (Figure 1B). Direct
activator BH3-only protein function can be mimicked by short00, March 2, 2012 ª2012 Elsevier Inc. 989
peptides derived from the BH3 domains of BID and BIM (referred
to as BID BH3 and BIM BH3) (Kuwana et al., 2005; Letai et al.,
2002). We compared the responses of the HM fraction versus
mitochondria to BID BH3 and BIM BH3 induced cyto c release.
The HM fraction treated with BID BH3 or BIM BH3 demonstrated
greater sensitivity to cyto c release compared to mitochondria
(Figure 1C), suggesting the effect was not specific to BID. To
ensure that the purification of mitochondria did not alter their
integrity, we measured their ability to respire and compared their
rates of O2 consumption to the original HM fraction. The HM frac-
tion and mitochondria exhibited similar rates of O2 consumption
(Figure S1A, available online), and mitochondria appeared
normal by electron microscopy (Figure S1B).
When mitochondria were purified from the HM fraction, there
was a loss of 30%–40% of protein, which was recovered in the
resulting mS fraction. We hypothesized that the mS fraction con-
tained an activity required for maintaining sensitivity to C8-BID.
Mitochondria alone incubated with C8-BID did not release
cyto c, but the addition of mS promoted dose-dependent release
of cyto c (Figure 1D). The combination of mS and BID BH3 also
promoted cyto c release (Figure 1D). For both C8-BID and BID
BH3 cooperation with mS, BCL-xL blocked cyto c release sug-
gesting that microsome-regulated MOMP proceeded through
BAK (Figure 1D). Cyto c and BAK levels did not change after
addition of mS (Figures 1E and 1F).
As low concentrations of C8-BID (0.1 nM) did not induce
MOMP in HM fractions, but the addition of solubilized mS syner-
gized with C8-BID to produce robust MOMP (Figures 1A and 1D
and Figure S1C), we subjected mS proteins to the enrichment
protocol shown in Figure 1G and monitored synergy with
C8-BID (Figures S1C-E, left). Peptide analysis of the final,
enriched preparation revealed the presence two neutral sphin-
gomyelinases (N-SMase; also referred to as SM phosphodies-
terases), SMPD3 and SMPD4. The MOMP-promoting fractions
were then examined for N-SMase activity by 14C-SM hydrolysis
(Figures S1C-E, right). N-SMase activity correlated with fractions
that synergized with C8-BID to promote MOMP. We therefore
directly examined the effects of N-SMases on MOMP.
A Neutral Sphingomyelinase Activity Cooperates with
the BCL-2 Family to Promote MOMP
To determine if SMPD3 or SMPD4 uniquely promoted MOMP,
we compared SMPD2, 3, and 4 for their ability to sensitize
WT HM fractions for C8-BID induced cyto c release. SMPD2,
SMPD3, and SMPD4 were in vitro transcribed and translated
(IVTT), and each was tested for 14C-SM hydrolysis (Figures 2A
and 2B). We next analyzed the IVTT proteins for their abilities
to promote C8-BID induced cyto c release. SMPD2-4 cooper-
ated with C8-BID to promote MOMP, which was blocked by
either the N-SMase inhibitor GW4869 or BCL-xL (Figure 2C).
These data suggest that mitochondria and C8-BID cooperate
with a general N-SMase activity. Furthermore, inhibition by
GW4869 and BCL-xL confirmed that MOMP was promoted via
SMase activity and through the activation of BAK, respectively
(Figures 2B and 2C).
To further examine the cooperation between C8-BID and
sphingolipid metabolism, we added a suboptimal concentration
of C8-BID to WT HM fractions in the presence of either a ceram-990 Cell 148, 988–1000, March 2, 2012 ª2012 Elsevier Inc.ide synthase inhibitor in the de novo synthetic pathway (FB1),
which does not rely on a SMase; or an inhibitor of SM synthase,
D609, which can demonstrate coupling between SMases and
SM synthases. A suboptimal concentration of C8-BID promoted
a small amount of cyto c release that was inhibited by D609, but
not FB1, further suggesting a potential role for a SMase inMOMP
(Figure 2D). As an additional control, we compared WT and acid
SMase knockout (asm/) HM fractions for their ability to sensi-
tize WT HM fractions for MOMP as in figure S1E, and observed
equivalent MOMP-promoting activities (Figures S2A–S2C). We
next tested an N-SMase from B. cereus (bSMase) for its ability
to cooperate with C8-BID. As shown in Figure 2D, bSMase pro-
moted a small but detectible amount of cyto c release in WT HM;
but when bSMase was titrated in the presence of C8-BID, the
release of cyto c was robust and complete.
The above results suggest that removal of contaminating
membranes from mitochondria reduced sensitivity to C8-BID
induced MOMP. We hypothesized that mitochondrial purifica-
tion from the HM fraction removed a SMase activity that was
necessary for normal sensitivity to C8-BID. To address this, total
liver homogenate, the HM fraction, and mitochondria were
compared for 14C-SM hydrolysis. Approximately two-thirds of
cellular N-SMase activity was lost during HM purification, yet
the remaining N-SMase activity was present in the HM fraction.
Limited proteolysis and further purification of mitochondria
reduced the activity to below 5% (Figure 2E). This suggests
that the N-SMase activity that cooperates with C8-BID is not
mitochondrial in origin, but is present in the heterotypic mem-
branes. To ensure that the purification protocol did not degrade
or inhibit the released N-SMase activity, we analyzed the HM
fraction, released heterotypic membranes, and mitochondria
during a time course of proteolysis for 14C-SM hydrolysis.
N-SMase activity in the HM fraction was released in a time-
dependent manner, remained active, and was recoverable
(Figure 2F). As controls, we monitored an ER luminal marker
(PDI) and cyto c to ensure appropriate loss of heterotypic
membrane species and equal analysis of mitochondria, respec-
tively (Figure 2F).
We chose to focus on SMPD3 as the significant MOMP-
promoting activity because it was consistently identified in our
assays (Figure 1G) and was amenable to recombinant protein
production (Figure 2I). We detected very few SMPD4 peptides
in our mass spectroscopy analyses and could not produce
recombinant SMPD4 after numerous attempts. Recombinant
mouse SMPD3 was tested for 14C-SM hydrolysis and demon-
strated significant activity (Figure 2I). SMPD3 was then analyzed
for its ability to cooperate with C8-BID to promote MOMP. Using
a WT HM fraction, we titrated suboptimal concentrations
of C8-BID in the presence of increasing SMPD3. C8-BID at
0.05-0.5 nM promoted minimal cyto c release, but this was
enhanced by the additional of SMPD3. For example, 0.5 nM
C8-BID treatment of the HM fraction released only small
amounts of cyto c; this was enhanced to nearly 100% release
in the presence of all SMPD3 concentrations tested (Figure 2G).
AsWT HM fractions contain only BAK, we sought to examine the
regulation of BAX-dependent MOMP by using a purified
bak/bax/ HM fraction. The addition of C8-BID and BAX re-
constituted BAX-dependent MOMP in the bak/bax/ HM
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B C Figure 2. A Neutral SMase Activity Cooper-
ates within the BCL-2 Family to Promote
MOMP
(A) SMPD2-4 IVTT with 35S-Met were subjected to
SDS-PAGE. Lines denoting 2, 3, and 4 indicate
full-length products.
(B) Nonradioactive IVTT reactions were performed
and subjected to 14C-SM hydrolysis ± 10 mM
GW4869.
(C) Nonradioactive IVTT reactions were performed
and combined with WT HM fractions. C8-BID
(1 nM for control; 0.05 nM for IVTT combinations);
GW4869 (25 mM) and BCL-xL (50 nM).
(D) WT HM fractions were pretreated with FB1
(1, 5, 10, and 25 mM), bSMase (0.0001, 0.0005,
0.0010, and 0.0025U) or D609 (1, 5, and 25 mM) for
1 hr at 37Cbefore the addition of 0.05 nMC8-BID.
(E) Liver homogenate, solubilized HM fraction, or
solubilized mitochondria (1 mg) were subjected to
14C-SM hydrolysis.
(F) HM fraction was subjected to limited proteol-
ysis (0, 1, 2, 5, 10, and 20 min) on ice, and frac-
tionated into pellet (mitochondria) and supernatant
(contains released mS) before 14C-SM hydrolysis
and western blot.
(G) WT HM fractions were combined with C8-BID
(0.05, 0.1, 0.5, and 1 nM) or as indicated in the
presence of SMPD3 (1, 5, and 20 ng) and BCL-xL
(500 nM).
(H) bak/bax/ HM fractions treated with
SMPD3 (20 ng; or 1, 20 ng), BAX (25 nM), C8-BID
(10 nM; or 1, 10 nM; or as indicated), and BCL-xL
(500 nM).
(I) SMPD3 was tested for 14C-SM hydrolysis
and compared to bSMase. All data are reported
as ± SD.
See also Figure S2.fraction (Figure 2H). A concentration of C8-BID (1 nM) that was
alone insufficient to promote MOMP was then added to BAX in
the presence of increasing SMPD3. The addition of SMPD3 co-
operated with 1 nM C8-BID and BAX to promote substantial
MOMP (Figure 2H). For both BAK and BAX-dependent MOMP,
the addition of BCL-xL blocked C8-BID induced cyto c release
(Figures 2G and 2H).
Pharmacological Inhibition of Sphingolipid Metabolism
Blocks MOMP
We next investigated a panel of SM pathway inhibitors to
examine their effects on C8-BID induced BAK activation. The
SM pathway products, enzymes, and inhibitors relevant to this
study are summarized in Figure 3A. WT HM fractions were pre-
incubated with increasing doses of GW4869, NOE (ceramidase
inhibitor), MAPP (ceramidase inhibitor), SKI (sphingosine ‘SPH’
kinase inhibitor), DMS (SPH kinase inhibitor), DOP (sphingo-Cell 148, 988–10sine-1-PO4 ‘S1P’ lyase inhibitor), or THI
(S1P lyase inhibitor) prior to the addition
of C8-BID and analyzed for cyto c release
(Figures 3B–3D). While none of the drugs
alone promoted MOMP; GW4869, NOE,
MAPP (Figure 3B), SKI, and DMS (Fig-ure 3C) completely blocked C8-BID induced cyto c release. In
the case of BAK-dependent MOMP, DOP and THI did not influ-
ence C8-BID induced cyto c release (Figure 3D).
These data suggest that S1P synthesis is essential for sensi-
tivity of BAK activation in response to C8-BID. To test this
hypothesis, a WT HM fraction and subsequent mitochondria
were purified in the presence of DOP and THI to prevent S1P
degradation. Mitochondria purified in the presence of DMSO
were incubated with increasing doses of C8-BID and demon-
strated resistance to C8-BID induced cyto c release (Figure 3E).
However, mitochondria purified in the presence of DOP and THI
demonstrated C8-BID sensitivity similar to the HM fraction (Fig-
ure 3E). Indeed, mitochondrial purification in the presence of
either DOP or THI prevented the degradation of S1P and levels
remained markedly higher compared with mitochondria purified
in the presence of DMSO (Figure 3F and Figure S3A). The result-
ing concentrations of mitochondrial S1P following DOP or THI00, March 2, 2012 ª2012 Elsevier Inc. 991
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Figure 3. Inhibition of the Sphingolipid
Pathway Blocks MOMP
(A) Substrates, products, and enzymes, together
with enzyme inhibitors tested.
(B–D) WT HM fractions were pretreated with the
indicated drugs for 1 hr at 37C prior to addition of
C8-BID (1 nM). GW4869 (2, 10, and 20 mM), MAPP
(2, 10, and 20 mM), NOE (0.1, 0.5, and 1 mM), DMS
(2.5, 12.5, and 25 mM), SKI (5, 25, and 50 mM), DOP
(1, 5, and 10 mM), THI (1, 5, and 10 mM).
(E) HM and subsequent mitochondria were puri-
fied in the presence of DOP/THI (10 mM each)
before treatment with C8-BID (0, 0.5, and 1 nM).
(F) The levels of S1P were measured following
isolation as in (E).
(G and H) bak/bax/ HM fractions were pre-
treated with drugs (two higher doses from above)
for 1 hr at 37Cprior to addition of BAX (25 nM) and
C8-BID (10 nM).
(I) The HM fraction was pretreated with the highest
doseof the inhibitors listed in (B)–(D) for1hr at37C,
prior toadditionofBAX (25nM)andC8-BID (10nM).
Reactions were then incubated for 1 hr at 37C
before lysis in 1% CHAPS buffer and IP. A MOMP
reaction lysed in 1% Triton X-100 is the positive
control. All graphed data are reported as ± SD.
See also Figure S3.inhibition equaled approximately 1.8 mM and 0.42 mM, respec-
tively. We based these calculations on 50 mg of mitochondrial
protein per 50 ml MOMP reaction equals 10 nmole of total lipid
Pi (Wagner and Rafael, 1977). As an example for DOP treatment,
91.118 pmoles of S1P/nmole lipid Pi was detected; therefore,
911.18 pmoles of S1P equals 1.8 mM S1P per 50 ml reaction.
As an additional control for the inhibitor studies, we analyzed
GW4869, NOE, and MAPP for their capacity to regulate
C8-BID induced MOMP in the absence of pretreatment (same
treatments as in Figure 3B). This control was done to ensure
that pretreatment was necessary as inhibition of MOMP fol-
lowing simultaneous drug and C8-BID treatment would likely
suggest these drugs are not directly affecting sphingolipid levels
(Figure S3B).
The same panel of SM pathway inhibitors was tested for their
influence on C8-BID induced BAX activation using bak/bax/
HM fractions. This fraction was preincubated with different992 Cell 148, 988–1000, March 2, 2012 ª2012 Elsevier Inc.doses of FB1, D609, GW4869, NOE,
MAPP, SKI, DMS, DOP, or THI prior to
the addition of BAX and C8-BID (Figures
3G and 3H). The inhibitors had no effect
on the HM fraction in the absence of
C8-BID and BAX (Figure 3G), but all
the sphingolipid metabolism inhibitors
blocked C8-BID plus BAX-induced cyto
c release (Figure 3H). We performed the
same assay as in Figures 3B–3D, but
also probed for SMAC to ensure the
effect is specific for MOMP and not cyto
c mobilization (Figure S3C).
BAX-dependent cyto c release is asso-
ciated with conformational changes atthe amino terminus of BAX, which is recognized with the confor-
mation-specific antibody, 6A7 (Hsu and Youle, 1997). To deter-
mine if the sphingolipid inhibitors blocked BAX conformational
changes, we preincubated bak/bax/ HM with the highest
doses of the drugs used in Figure 3H for 1 hr, prior to the addi-
tion of BAX and C8-BID. The reactions were lysed and sub-
jected to 6A7 immunoprecipitation (IP). The addition of C8-BID
to the DMSO-treated HM fraction lead to 6A7-positive BAX.
However, pretreatment with D609, GW4869, NOE, MAPP, SKI,
DMS, DOP, or THI, but not FB1, led to no 6A7-positive BAX (Fig-
ure 3I). Furthermore, the same sphingolipid inhibitors that
prevent BAX structural rearrangements also lead to the inhibi-
tion of BAX oligomerization (Figure S3D). These data suggest
that a SM metabolic product beyond S1P is essential for sensi-
tivity to C8-BID induced BAX activation (Figures 3H and 3I),
which contrasts to the lipid requirement for BAK-dependent
MOMP (Figure 3D).
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Figure 4. Reconstitution of the Sphingolipid
Pathway Replaces the Heterotypic
Membrane Requirement for MOMP
(A) Purified mitochondria were preincubated for
1 hr with indicated sphingolipids (SM or C16,
1 mM), purified sphingolipid enzymes (bSMase or
ASAH2, 0.001 U/ml) or drugs (GW4869 or MAPP,
25 mM) before the addition of C8-BID (1 nM). SPH
was added at 0.1 or 1 mM.
(B) WT mitochondria were incubated with indi-
cated sphingolipids (0.1, 0.5, and 1 mM) prior to
the addition of C8-BID (1 nM). As a positive con-
trol, purified mS (50 mg) was also tested for
sensitization.
(C) bak/bax/ mitochondria were treated with
indicated sphingolipids (1 mM).
(D) bak/bax/ HM fractions and mitochondria
were pretreated with BAX (25 nM), C8-BID (10 nM),
and indicated sphingolipids (0.1 and 1 mM).
(E) BAX was incubated with hex (0.1, 0.5, and
1 mM) and C8-BID (5, 10, and 25 nM) for 1 hr at
37C before IP with anti-BAX 6A7. Triton X-100
(0.5%) was added as a positive control for deter-
gent-treatment activation.
(F) LUVs (PC, PE, PI, PS, no CL) were treated with
indicated proteins and hex.
(G) Mitochondria were pretreated with CsA
(100 nM) for 1 hr at 37C prior to the addition of
S1P (0.1, 0.5, and 1 mM) and C8-BID (1 nM). All
data are reported as ± SD.
See also Figure S4.Reconstitution of SphingolipidMetabolismReplaces the
Heterotypic Membrane Requirement for MOMP
To examine further if BAK and BAX-dependent cyto c release
require different components of the SM pathway, we reconsti-
tuted the sphingolipid pathway with purified enzymes and lipids
in the presence of WT or bak/bax/mitochondria. SM hydro-
lysis to ceramide was recapitulated by combining bSMase, SM,
andWTmitochondria. After 1 hr incubation at 37C, C8-BID was
added. Reconstitution of SM hydrolysis alone did not promote
MOMP, but the addition of C8-BID allowed for cyto c release,
which was blocked by GW4869 (Figure 4A). The conversion of
ceramide to SPH was recapitulated by combining recombinant
N-acylsphingosine amidohydrolase 2 (ASAH2, neutral cerami-
dase), C16-Ceramide (C16), and WT mitochondria. After 1 hr
incubation at 37C, C8-BID was added. Reconstitution ofCell 148, 988–10ceramide hydrolysis alone did not pro-
mote MOMP, but the addition of C8-BID
allowed for cyto c release, which was
blocked by MAPP (Figure 4A). The con-
version of ceramide to SPH was also re-
capitulated by combining SPH and WT
mitochondria. SPH treatment alone did
not promote MOMP, but the addition of
C8-BID allowed for cyto c release, which
was insensitive to both GW4869 and
MAPP (Figure 4A). These data suggest
that SPH is upstream of C8-BID induced
BAK activation and MOMP.Sphingolipid metabolites ranging from SM to ortho-phos-
phoethanolamine (OPEA) and hexadecenal (hex) were examined
for their ability to sensitize WT mitochondria for C8-BID induced
BAK activation. SM, C16, SPH, S1P, OPEA, and hex were
titrated on WT mitochondria in the presence of C8-BID. The
sphingolipids and C8-BID were added simultaneously to thwart
the conversion of intermediates by mitochondrial sphingolipid
enzymes. Based on our results in Figure 3F and the calculations
detailed above, we used an average of the DOP and THI induced
S1P concentrations (1.8 mM and 0.42 mM, respectively) as a
benchmark for an approximate physiological concentration of
sphingolipids to examine per assay (0.1, 0.5, and 1 mM). As
shown in Figure 4B, the combination of S1P and C8-BID resulted
in the complete release of cyto c. The same experiment was then
conducted using bak/bax/ mitochondria combined with00, March 2, 2012 ª2012 Elsevier Inc. 993
BAX, and C8-BID induced BAX-dependent MOMP was recon-
stituted by the fatty aldehyde, hex (Figure 4D). None of the
sphingolipid metabolites alone had an observable effect on
bak/bax/ mitochondria (Figure 4C); and the bak/bax/
HM fraction responded to C8-BID and BAX as expected (Fig-
ure 4D). These results suggest that BAK and BAX-dependent
MOMP require different components of the sphingolipid
pathway: BAK cooperates with S1P, while BAX cooperates
with hex.
To determine if hex promoted BAX activation and subsequent
6A7 positivity, we titrated C8-BID and hexwith recombinant BAX
(Figure 4E). Titration of hex or C8-BID with BAX did not promote
6A7 IP, but the combined treatment of C8-BID, hex, and BAX
promoted dose-dependent 6A7 positivity (Figure 4E).
BAX, BID, and hex cooperation was examined using a large
unilamellar vesicles (LUV) model system that faithfully measures
BAX activation (Kuwana et al., 2002). LUVs containing 7% car-
diolipin (CL) are generally used to promote BAX and C8-BID
synergy and permeabilization, but CL is not highly represented
at the OMM. Therefore, CL-free LUVs were examined for BAX
function by combining them with C8-BID and titrating hex (Fig-
ure 4F). BAX, N/C-BID, and hex separately did not promote
LUV permeabilization, and the combined treatment of BAX and
N/C-BID resulted in only minimal release (Figure 4F). BAX and
N/C-BID combined with hex caused dose-dependent permeabi-
lization of the LUVs suggesting BAX, N/C-BID, and hex cooper-
ation in BAX-mediated membrane permeabilization (Figure 4F).
Importantly, the exogenous addition of ceramide, SPH, or S1P
did not promote BAX activation to similar degrees as hex
(Figures S4A and S4B). For additional control and comparison,
we generated LUVs where the 7% CL was replaced with ceram-
ide, SPH, or S1P, but none of these LUVs promoted efficient BAX
activation compared to hex (Figure S4C). Together, these data
suggest that hex can directly regulate BAX and BID function to
promote MOMP.
One alternative explanation for S1P regulation of C8-BID
induced, BAK-dependent cyto c release could be that sphingo-
lipid metabolism induces transient openings of themitochondrial
permeability transition pore (MPTP) impacting on sensitivity to
MOMP (Scorrano et al., 2002). To test this, we determined if
S1P regulation of C8-BID induced, BAK-dependent cyto c re-
lease was sensitive to cyclosporine A (CsA), an inhibitor of
MPTP. As shown in Figure 4G, S1P and C8-BID promoted
BAK-dependent cyto c release that was insensitive to CsA, sug-
gesting the MPTP was not involved.
Hexadecenal Binds and Promotes BAX Activation
We noted that mid-range mM concentrations of hex directly
promoted BAX activation akin to detergent treatment (Figures
S4A and S4B). We took advantage of this observation to better
understand the functional relationship between BAX and hex.
Sphingolipid metabolites ranging fromSM to hexwere examined
for their ability to directly induce BAX activation as measured by
oligomerization (Figure 5A). BAXwas treatedwith SM, C16, SPH,
S1P, OPEA, or hex in the presence of BMH before analyzing olig-
omerization. All doses of hex promoted BAX oligomerization,
whereas S1P promoted only weak BAX activation (Figure 5A).
Octylglucoside (OG) and CHAPS were positive and negative994 Cell 148, 988–1000, March 2, 2012 ª2012 Elsevier Inc.controls in the assay, respectively. To determine if the BAX olig-
omers in Figure 5A could induce MOMP, the sphingolipid or
detergent treated BAX samples were extensively dialyzed
after treatment and added to bak/bax/ mitochondria. In-
deed, hex-activated BAX induced MOMP and cyto c release
(Figure 5B).
The ability of hex to directly promote BAX oligomerization
suggests that BAX and hex physically associate. To determine
the specificity of this association, we analyzed the binding of
BAX to commercially available sphingolipid arrays (Figures S5A
and S5B). BAX was incubated with the sphingolipid arrays
according to the manufacturer’s protocol, but we observed no
detectable binding between BAX and the lipids tested. We there-
fore compared the binding of BAX to S1P and hex with a chloro-
form-spotted array using the same detection methods and
observed a dose-dependent, BAX-hex association (Figure S5C
and Figures 5C and 5D). The same assay was repeated com-
paring BAX and BCL-xL for hex binding, and while BAX bound
to hex, a BCL-xL-hex interaction was not observed, suggesting
that the binding of hex to the BAX protein is specific (Figure 5D).
An immunoprecipitating antibody against BAX or BCL-xL was
spotted onto the arrays as a positive control for the protein
capture and detection conditions (Figure 5D). To probe the spec-
ificity of the hex-BAX association, hex and a closely related com-
pound, hexadecanal, were titrated in the presence of BAX and
BMH before analyzing BAX oligomerization (Figure 5E). Hex
induced dose-dependent BAX oligomerization, whereas hexa-
decanal did not, suggesting that not all long chain aldehydes
have the ability to induce BAX activation.
Sphingolipid Metabolism Regulates Sensitivity
to Apoptosis and Clonogenic Survival
We tested whether the sphingolipid pathway regulates mito-
chondrial sensitivity to BAK and BAX activation and MOMP in
a cellular context by observing the effect of enhancing or in-
hibiting sphingolipid metabolism. As a cellular model for death
receptor-mediated, BID-dependent apoptosis, HeLa cells were
titrated with different doses of TNF in the presence of cyclohex-
amide (CHX) and analyzed 8h later to determine an appropriate
TNF concentration for further study. HeLa cells did not respond
to TNF or CHX treatment alone; but they underwent dose-
dependent apoptosis with TNF in the presence of CHX (Fig-
ure 6A). In a parallel experiment, we transiently transfected
empty vector, SMPD3, or SMPD4. The exogenous expression
of SMPD3 or SMPD4 enhanced the basal level of apoptosis,
but not markedly, and the response 24 hr posttransfection did
not increase when analyzed 48 and 72 hr posttransfection (Fig-
ure 6A and data not shown). We then examined the effect of
exogenous SMPD3 or SMPD4 expression on TNF-induced apo-
ptosis. We observed that the exogenous expression of SMPD3
or SMPD4 greatly enhanced sensitivity to TNF-induced apo-
ptosis in a dose-dependent manner, whereas expression of
the vector alone did not influence survival (Figure 6B).
As BH3-only proteins are essential to the induction of MOMP,
we tested if SMPD3 cooperated with exogenous BH3-only
protein expression to promote apoptosis. We chose to evaluate
three BH3-only proteins: BIM-S and tBID, two well-defined
direct activator BH3-only proteins and potent inducers of
oligomer
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Figure 5. Hexadecenal Binds and Promotes
BAX Activation
(A) BAX (10 nM) was incubated with indicated
lipids or detergents (0.1 and 1mM) in the presence
of BMH (100 nM) for 1 hr at 37C before western
blot.
(B) As in (A), but instead of oligomerization anal-
ysis, samples were extensively dialyzed, com-
bined with bak/bax/ HM, and incubated for
1 hr at 37C before fractionation, and western blot
for cyto c.
(C and D) Nitrocellulose membranes spotted with
indicated picomoles of S1P or hex (combined with
BSA and ponceau red for visualization) were
incubated with either 50 ng of BCL-xL or BAX and
probed with anti-BCL-xL or anti-BAX (horizontal
mark for anti-BCL-xL, vertical for anti-BAX). The
positive controls (*) on the blots are spots con-
taining an IP antibody for BCL-xL or BAX.
(E) BAX (10 nM) was incubated with hexadecanal
or hex (0, 0.1, 1, 5, and 10 mM) in the presence of
BMH (100 nM) for 1 hr at 37C.
See also Figure S5.apoptosis; and BAD, a de-repressor BH3-only protein that is not
a strong inducer of apoptosis (Kuwana et al., 2005; Letai et al.,
2002). WT mouse embryonic fibroblasts (MEFs) were transiently
transfected with either empty vector or SMPD3 in the presence
of increasingmasses of BIM-S, BAD, or tBID cDNA and analyzed
24 hr later. As shown in Figure S6A, BIM-S and tBID expression
demonstrated dose-dependent induction of apoptosis, and this
was enhanced by SMPD3 expression. BAD expression alone did
not induce marked apoptosis, as expected, but there was an
observable cooperation between BAD and SMPD3. To ensure
that these observations were due to the enzymatic activity of
SMPD3, we tested two SMPD3 catalytic mutants (SMPD3D428ACell 148, 988–10and SMPD3H639A) for synergy with
BIM-S (Milhas et al., 2010). While WT
SMPD3 synergized with BIM-S in a
dose-dependent manner, both SMPD3
mutants failed to synergize with BIM-S
to promote apoptosis (Figure S6B). We
probed BCL-2 family expression fol-
lowing SMPD3 and SMPD4 transient
expression to ensure that the enhanced
apoptosis was not due to changes in
pro- or antiapoptotic protein expression
(Figure S6C).
Our study suggests that a SPH kinase
activity is required upstream of both
BAK- and BAX-dependent MOMP. To
examine this requirement in cells, we
used WT MEFs in which sphk1 or sphk2
was silenced by RNAi and tested their
sensitivity to TNF-induced apoptosis.
Lysates from the sphk1 and sphk2 knock-
down cells were confirmed for downre-
gulation of SPHK1 and SPHK2 protein
(Figure 6C). Control, sphk1, and sphk2RNAi cell lines were then treated with CHX and TNF, cultured
for 6 hr, and analyzed by flow cytometry (Figure 6D). Control
and sphk1 RNAi cells were sensitive to TNF-induced apoptosis;
however, the loss of sphk2 expression resulted in resistance to
apoptosis (Figure 6D). Silencing of sphk2 in MEFs also resulted
inmarked resistance to theActD inducedapoptosis (Figure S6D).
Reduction in apoptosis was not due to changes in BCL-2 family
expression following sphk2 knockdown (Figure S6E).
As loss of sphk2 expression correlated with reduced apo-
ptosis and our previous data demonstrate that changes in S1P
regulate mitochondrial sensitivity to MOMP, we evaluated
the subcellular localization of SPHK2. While the HM fraction00, March 2, 2012 ª2012 Elsevier Inc. 995
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Figure 6. SMPD3 and SMPD4 Regulate Sensitivity to Apoptosis, and a Mitochondrial Sphingosine Kinase Activity Sensitizes for MOMP
(A) HeLa cells were transfected with vector, SMPD3, or SMPD4; or treated with CHX (10 mg/ml), TNF (25 ng/ml; or 5, 10, 15, 20, and 25 ng/ml); cultured for 24 hr
and stained with Annexin V-PE.
(B) HeLa cells were transfected with 100, 500, 1000 ng of vector, SMPD3 or SMPD4, cultured for 24 hr, treated with CHX (10 mg/ml) and TNF (15 ng/ml), cultured
for 6 hr and stained with Annexin V-PE.
(C) WT MEFs retrovirally infected to silence sphk1 or sphk2 were analyzed by western blot.
(D) Control, sphk1, and sphk2 RNAi cell lines were treated with CHX (5 mg/ml) and TNF (10 ng/ml), cultured for 6 hr, and stained with Annexin V-PE.
(E) HM fraction, mitochondria, and mS were subjected to western blot.
(F) WT HM fractions were treated with C8-BID (5, 25, 1000* pM, *positive control), SPHK1 (25 ng), SPHK2 (25 ng), BCL-xL (50 nM) in MAB or RB.
See also Figure S6.contained both SPHK1 and SPHK2, the majority of SPHK1 and
SPHK2 were localized to the mS and mitochondria, respectively.
The purity of the fractions was confirmed by localization of PDI
and cyto c (Figure 6E). SPHK2 activity was also analyzed by an
enzymatic assay specific to SPHK2 comparing mS and mito-
chondria; and this confirmed that mitochondria contain func-
tional SPHK2 (Figures S6F and S6G). We also compared the
endogenous mitochondrial SPHK2 activity against recombi-
nant SPHK2 to ensure specificity within our assay (Figures S6F
and S6G).
To directly test the role of SPHK2 in regulating sensitivity
to C8-BID, we analyzed the influence of SPHK2 (Figures S6F
and S6G) on mediating C8-BID induced, BAK activation, and
MOMP. WT HM fractions were treated with C8-BID in the pres-996 Cell 148, 988–1000, March 2, 2012 ª2012 Elsevier Inc.ence or absence of SPHK2. Neither C8-BID at 5 or 25 pM, nor
SPHK2 independently promoted MOMP, but when combined,
C8-BID and SPHK2 induced complete cyto c release that was
inhibited by BCL-xL (Figure 6F, lower panels). Using traditional
MOMP conditions, our pharmacological inhibitor data in Figures
3C and 3H demonstrate that a SPH kinase is active, suggesting
that this enzyme has access to a residual ATP pool within the HM
fraction. As we are adding SPHK2 to the reactions and the
accessibility of the ATP pool was unknown, we provided a
means of ATP production. We comparedMOMP reactions using
mitochondrial assay buffer (MAB, typical buffer used in MOMP
assays, no additional ATP source, upper panels), and respiration
buffer (RB, supplemented with mitochondrial complex sub-
strates and ADP to generate ATP, lower panels), and observed
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Figure 7. The SMase Pathway Regulates Sensi-
tivity to Apoptosis
(A) HeLa cells were pretreated with indicated pharmaco-
logical inhibitors for 6 hr, apoptotic inducers (CH11/CHX,
0.4 mg/ml + 10 mg/ml CHX; 30 ng/ml TNF + 10 mg/ml CHX;
or 50 nM ActD) added for 24 hr, and colonies were stained
with methylene blue 12 days later. S1P (0.25 mM) was
added at the same time as the inhibitors.
(B–D) Colonies from CH11/CHX, TNF/CHX, and ActD
treatments are shown. Wells were treated as indicated
(top to bottom, left to right): (1) DMSO, (2) 50 mM D609, (3)
20 mM GW4869, (4) 100 mM DOP, (5) 100 mM THI, and (6)
0.25 mM S1P.
All data are reported as ± SD. See also Figure S7.that the effect of SPHK2 indeed required an ATP source (Fig-
ure 6F, compare upper and lower panels). Additionally, we
examined recombinant SPHK1 plus C8-BID and also observed
a MOMP-promoting activity, albeit less than with SPHK2, sug-
gesting that the mitochondrial localization of SPHK2 likely
promotes MOMP (Figure 6F).
We next tested several pharmacological regulators of the
sphingolipid pathway to determine their influence on cellular
apoptosis and clonogenic survival. HeLa cells were treated with
all the previous inhibitors of sphingolipid metabolism; however,
only D609, GW4869, DMS, SKI, DOP, and THI permitted further
analysis as the other drugs (FB1, MAPP, and NOE) were toxic
at the doses and/or treatment times required for the survival
assays (Figure S7A, and data not shown). HeLa cells were pre-
treatedwithD609,GW4869,DMS,SKI, DOP, andTHI for 6 h; pro-
apoptotic stimulation was added, cells were cultured for 24 hr,
and analyzed. D609, GW4869, DMS, SKI, DOP, and THI each af-
forded protection from the three proapoptotic stimuli, suggesting
that pharmacologically targeting the sphingolipid metabolic
pathway at various stages can directly impact on cellular survival
(Figures S7B-D). Moreover, the clonogenic potential of these
cells was also assayed; however, DMS and SKI were toxic in
this assay and could not be evaluated (data not shown). As in
Figures S7B–S7D, HeLa cells were pretreated with D609,
GW4869, DOP, and THI, proapoptotic stimulation was added
and maintained for 12 hr, then cultured for two weeks prior to
staining with methylene blue. Inhibition of N-SMase activity or
the S1P lyase activity resulted in observable clonogenic survival
despite apoptosis signaling through theextrinsic or intrinsic path-
ways (Figures 7A–7D). As a control for the loss of S1P lyase func-
tion, which could result in enhanced extracellular S1P signaling,
a S1P treatment group was also included, but this did not result
in enhanced clonogenic survival (Pyne et al., 2009).
DISCUSSION
Prior to the elucidation of caspase-activation mechanisms,
a prominent notion held that SM hydrolysis and subsequent
ceramide formation had a direct fundamental role in engaging
cell death (Obeid et al., 1993); yet molecular mechanismsCell 148, 9whereby ceramide initiates and executes
apoptosis have been scant (Bartke andHannun,
2009). A direct role for ceramide in mitochon-drial integrity has been proposed (Siskind et al., 2002, 2006),
but our studies suggest an alternative mechanistic view, such
that ceramide is a precursor of two molecules, S1P and hex,
which facilitate BAK/BAX activation leading to MOMP.
We propose that ceramide is produced by the constitutive
hydrolysis of SM by a N-SMase in a mitochondria-associated
compartment. Ceramide is then transferred to mitochondria,
where enzymes further convert ceramide to produce S1P and
hex. Indeed, evidence exists that N-SMases are associated
with the heavy and light membrane fractions, and ceramide
transport between organelles is described (Hanada et al.,
2009; Sawai et al., 2000; Stiban et al., 2008; Wu et al., 2010;
Yabu et al., 2009). Upon purification of mitochondria from the
HM fraction, sensitivity to C8-BID induced BAK/BAX activation
rapidly wanes unless components of the sphingolipid pathway
are provided or metabolism is inhibited. We propose that mito-
chondria may regulate their sphingolipid composition through
both forward (ceramide - SPH - S1P) and reverse pathways
(S1P - SPH - ceramide).
SM hydrolysis and subsequent changes in sphingolipid
profiles are associated with enhanced sensitivity to proapoptotic
stimulation. In breast cancer cells, a bSMase targeted to mito-
chondriawas shown to promote apoptosis, and it was suggested
that mitochondrial SM hydrolysis enhanced BAX mitochondrial
translocation (Birbes et al., 2001, 2005). Proapoptotic stimuli
promoteSMhydrolysis andmarked alterations to the intracellular
sphingolipid profile, perhaps to establish the appropriate milieu
at the OMM to promote BAK/BAX function. For instance, TNF
specifically induces SMPD3 function in MCF-7 cells to promote
SMhydrolysis to ceramide (Clarke et al., 2011). Indeed, ceramide
has been suggested to directly regulate the permeabilization
function of BAX using isolated mitochondria and phospholipid
membranes; and a recent report suggests that mitochondrial
macrodomains rich in ceramide promote BAX activity (Ganesan
et al., 2010; Lee et al., 2011). In support of this hypothesis,
reversing sphingolipid metabolism to favor SM accumulation
decreased sensitivity to BAX-mediated death (Yang et al., 2006).
Earlier observations suggested that CL is required for MOMP,
however the presence of this lipid in the OMM is controversial
(Kuwana et al., 2002; Lutter et al., 2000; Ott et al., 2009). Our88–1000, March 2, 2012 ª2012 Elsevier Inc. 997
studies suggest that mitochondria interact with distinct cellular
components to establish the sphingolipid milieu that is compat-
iblewithMOMP. Indeed, we have found that lipid vesicles lacking
CL can be permeabilized by the combination of BID and BAX,
provided hex is present. Several proteins (e.g., DRP-1, MTCH2,
OPA-1, and TOM22) are also implicated in orchestrating
MOMP, by coordinating BAX and/or BID function at the OMM
or by directly regulating the mitochondrial network, and it will
be necessary to determine how S1P and hex potentially coop-
erate with the above proteins to fully appreciate the mechanisms
that control BAK and BAX activation (Bellot et al., 2007; Cassidy-
Stone et al., 2008; Montessuit et al., 2010; Yamaguchi et al.,
2008; Zaltsman et al., 2010). Structural and biochemical studies
suggest that BAK/BAXactivation involves adisplacement of helix
a1, leading to distal exposure of the BH3 region of these mole-
cules (Dewson et al., 2008; Gavathiotis et al., 2008). The binding
of S1P to BAK, or hex to BAX, may act to lower the thermody-
namic constraints on these conformational changes. In support
of this idea, we found that BID-induced exposure the 6A7 epitope
on BAX is facilitated by hex, which directly binds to BAX.
TNF- and UV-induced apoptosis are reported to signal
through N-SMase-regulated pathways (Clarke et al., 2011; Dai
et al., 2004; Luberto et al., 2002). We also observed that several
such inhibitors act to preserve cell survival following treatments
that normally induce apoptosis. These observations support the
idea that downstream components of the pathway, such as S1P
and hex, promote MOMP and cell death. Our finding that S1P
lyase inhibitors supported cell survival (where potentially BAK
activation, facilitated by S1P could still occur) is consistent
with the protective effects of bax deletion in cells (Zhang et al.,
2000). Interestingly, S1P lyase deficiency is described to
promote DNA damage resistance and enhanced tumor xeno-
graft formation (Colie et al., 2009; Oskouian et al., 2006). The
expression of S1P lyase is also reduced in colon cancer cells,
which are suggested to primarily utilize BAX to promote apo-
ptosis highlighting the potential cooperation between BAX and
SPH lyase function and its products (Oskouian et al., 2006).
Ceramide production can occur in cells independently of the
N-SMases, such as by acidic SMase or ceramide synthase,
both of which can be activated by stress conditions (Kolesnick
and Fuks, 2003; Santana et al., 1996). Increased ceramide
production by these mechanisms may contribute to MOMP by
providing precursors at the OMM. S1P lyase appears to directly
impact on cellular survival following DNA damage, and studies
suggest that hex coordinates apoptosis through BID, BIM, and
BAX (Kumar et al., 2011a; Kumar et al., 2011b). Finally, SMPD3
is lost or mutated in a subset of human lymphomas (Kim et al.,
2008), and theSMPD3promoter is shown tobehyper-methylated
in aggressive breast tumors (Demircan et al., 2009). It is tempting
to speculate that such changes can facilitate cell survival by
restricting MOMP through the mechanisms we describe.EXPERIMENTAL PROCEDURES
Heavy Membrane Fractions, Mitochondrial Purification, and Cyto-c
Release Assay
Heavy membrane fractions were purified from murine liver using dounce
homogenization and differential centrifugation in mitochondrial isolation998 Cell 148, 988–1000, March 2, 2012 ª2012 Elsevier Inc.buffer. To purify mitochondria from the HM fraction, the HM fraction was
prepared in the absence of BSA, and 1 mg/mg of proteomics grade trypsin
was added and incubated on ice for 10 min. Soybean trypsin inhibitor
(10 mg/mg trypsin) was added, incubated on ice for 30 min, and the trypsinized
fraction was loaded on top of a 26%/60%Percoll gradient. Mitochondria at the
26%/60% Percoll interface were removed with an 18 gauge syringe, and
washed twice in MIB. For MOMP assays, HM fractions or mitochondria were
incubated in MIB supplemented to 110 mM KCl (mitochondrial assay buffer,
MAB), plus or minus proteins and lipids for 1 hr at 37C. Reactions were
then centrifuged at 5,5003 g for 10 min, the resulting pellets and supernatants
were analyzed for cyto c by SDS-PAGE and western blot. For high throughput,
total cyto cwas occasionally determined by a sample containing mitochondria
solubilized in 1% CHAPS instead of analyzing the pellet fractions.Acidic and N-SMase Assay
For acidic SMase (asm) analysis, samples were prepared in 0.2 M sodium
acetate pH 5.0 and 0.1% Triton X-100. For N-SMase analysis, samples were
prepared in 25 mM Tris-HCl (pH 7.4), 5 mM EDTA and 0.2% Triton X-100.
Samples were incubated for 30 min at 37C, subjected to Folch extraction
and the amount of choline-methyl-14C release was measured by scintillation
counting.Survival Assays
HeLa cells and MEFs were transfected, then treated with TNF and CHX,
cultured for 24 hr, harvested by trypsinization, stained with AnnexinV and
analyzed by flow cytometry. For pharmacological inhibitor studies, HeLa cells
were pretreated with indicated pharmacological inhibitors of the SM pathway
for 6 hr before apoptotic inducers (anti-Fas/CD95 antibody TNF or ActD) were
added. For clonogenic survival studies, HeLa cells were pretreated with indi-
cated pharmacological inhibitors of the SM pathway for 6 hr, apoptotic
inducers added, and cells cultured for 12 hr before changing the media. Colo-
nies were stained with methylene blue 12 days after treatment.
Please see the online Extended Experimental Procedures for more details.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at doi:10.1016/j.cell.
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